Daniel Kenny has almost 30 years of experience in the global pharmaceutical and medical device industry. He is an accomplished and proven biopharmaceutical business leader and in his career, he has developed and successfully driven business with industry leaders such as Roche, Allergan and Baxter working in Australia, EMEA and the US.
Prior to becoming chief executive of OncoSil Medical from January 2015 to December 2020, Mr Kenny was chief commercial officer of ABIVAX, a Paris-based global biopharmaceutical company specialising in the development of novel vaccines and anti-virals. At Baxter, he was global franchise head of vaccines and oversaw all franchise operations. Mr Kenny was also vice president of Baxter BioScience, EMEA with responsibility for all marketing and key business programmes in support of regional sales exceeding $1.9bio; at Roche as global lifecycle leader for Roaccutance, a product generating sales in excess of CHF 1.1 bio (2002), assuming responsibility for all global strategic marketing and business development activities; as international medical manager and medical science and safety team leader responsible for post-NDA clinical development strategy and critical issue work-ups for regulatory authorities.
Mr Kenny completed over 10 years in clinical research in the fields of ophthalmology with the Royal Australian College of Ophthalmologists and the University of Sydney and HIV/AIDS research at the University of New South Wales, Sydney, Australia prior to joining the pharmaceutical industry.
He is a graduate in Physics from the University of New South Wales, completed Executive Business Studies at both INSEAD and London Business School, a graduate of the Australian Institute of Physics, and a member of the Australian Institute of Company Directors.
